Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer

Thomas S Frank; Xiaotian Sun; Yuqing Zhang; Jingxuan Yang; William E Fisher; Marie-Claude Gingras; Min Li

doi:10.1016/j.canlet.2015.04.009

Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer

Cancer Lett. 2015 Jul 10;363(1):1-6. doi: 10.1016/j.canlet.2015.04.009. Epub 2015 Apr 15.

Authors

Thomas S Frank¹, Xiaotian Sun², Yuqing Zhang³, Jingxuan Yang⁴, William E Fisher⁵, Marie-Claude Gingras⁶, Min Li⁷

Affiliations

¹ The Vivian L. Smith Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA.
² The Vivian L. Smith Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA; Department of Medicine, Department of Surgery, The University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1262A, Oklahoma City, OK 73104, USA; Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
³ Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
⁴ The Vivian L. Smith Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA; Department of Medicine, Department of Surgery, The University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1262A, Oklahoma City, OK 73104, USA.
⁵ Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
⁶ Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA; Human Genome Sequencing Center, Baylor College of Medicine, One Baylor Plaza, N1519, Houston, TX 77030, USA. Electronic address: mgingras@bcm.edu.
⁷ The Vivian L. Smith Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA; Department of Medicine, Department of Surgery, The University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1262A, Oklahoma City, OK 73104, USA. Electronic address: min-li@ouhsc.edu.

Abstract

Pancreatic cancer has the worst five-year survival rate of all malignancies due to its aggressive progression and resistance to therapy. Current therapies are limited to gemcitabine-based chemotherapeutics, surgery, and radiation. The current trend toward "personalized genomic medicine" has the potential to improve the treatment options for pancreatic cancer. Gene identification and genetic alterations like single nucleotide polymorphisms and mutations will allow physicians to predict the efficacy and toxicity of drugs, which could help diagnose pancreatic cancer, guide neoadjuvant or adjuvant treatment, and evaluate patients' prognosis. This article reviews the multifaceted roles of genomics and pharmacogenomics in pancreatic cancer.

Keywords: Gene therapy; Genomic profiling; Mutations; Pancreatic cancer; Pharmacogenomics; SLC39A4 (ZIP4).

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor / genetics*
Biomarkers, Tumor / metabolism
Drug Resistance, Neoplasm / genetics
Gene Expression Profiling*
Genetic Predisposition to Disease
Genomics / methods*
Humans
Molecular Targeted Therapy*
Pancreatic Neoplasms / drug therapy*
Pancreatic Neoplasms / genetics*
Pancreatic Neoplasms / metabolism
Pancreatic Neoplasms / pathology
Patient Selection
Pharmacogenetics
Phenotype
Precision Medicine*
Predictive Value of Tests
Signal Transduction / drug effects

Substances

Antineoplastic Agents
Biomarkers, Tumor

Abstract

Publication types

MeSH terms

Substances

Grants and funding